These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16370181)

  • 1. Drug-drug interaction studies on first-line anti-tuberculosis drugs.
    Bhutani H; Singh S; Jindal KC
    Pharm Dev Technol; 2005; 10(4):517-24. PubMed ID: 16370181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs.
    Bhutani H; Singh S; Jindal KC; Chakraborti AK
    J Pharm Biomed Anal; 2005 Oct; 39(5):892-9. PubMed ID: 15978767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal.
    Battini S; Mannava MKC; Nangia A
    J Pharm Sci; 2018 Jun; 107(6):1667-1679. PubMed ID: 29462633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavior of uptake of moisture by drugs and excipients under accelerated conditions of temperature and humidity in the absence and the presence of light. 1. Pure anti-tuberculosis drugs and their combinations.
    Singh S; Bhutani H; Mariappan TT; Kaur H; Bajaj M; Pakhale S
    Int J Pharm; 2002 Oct; 245(1-2):37-44. PubMed ID: 12270240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S; Mohan B
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An explanation for the physical instability of a marketed fixed dose combination (FDC) formulation containing isoniazid and ethambutol and proposed solutions.
    Bhutani H; Mariappan TT; Singh S
    Drug Dev Ind Pharm; 2004 Jul; 30(6):667-72. PubMed ID: 15285340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG; Lötter AP
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
    [No Abstract]   [Full Text] [Related]  

  • 8. Compatibility Between Four Anti-TB Drugs and Tablet Excipients Determined By Microcalorimetry.
    Aucamp M; Liebenberg W; Okaecwe T; Geldenhuys M; Stieger N
    Pharmazie; 2019 Jun; 74(6):350-351. PubMed ID: 31138372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LC-MS/TOF and UHPLC-MS/MS study of in vivo fate of rifamycin isonicotinyl hydrazone formed on oral co-administration of rifampicin and isoniazid.
    Prasad B; Singh S
    J Pharm Biomed Anal; 2010 Jul; 52(3):377-83. PubMed ID: 19692195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
    Danckwerts MP; Ebrahim S; Pillay V
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the interaction between rifapentine and isoniazid under acid conditions.
    Prasad B; Bhutani H; Singh S
    J Pharm Biomed Anal; 2006 Jun; 41(4):1438-41. PubMed ID: 16621412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissolution testing of isoniazid, rifampicin, pyrazinamide and ethambutol tablets using near-infrared spectroscopy (NIRS) and multivariate calibration.
    de Oliveira Neves AC; Soares GM; de Morais SC; da Costa FS; Porto DL; de Lima KM
    J Pharm Biomed Anal; 2012 Jan; 57():115-9. PubMed ID: 21908131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entrapment of multiple anti-Tb drugs in microemulsion system: quantitative analysis, stability, and in vitro release studies.
    Mehta SK; Kaur G; Bhasin KK
    J Pharm Sci; 2010 Apr; 99(4):1896-911. PubMed ID: 19894276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin.
    Mohan B; Sharda N; Singh S
    J Pharm Biomed Anal; 2003 Mar; 31(3):607-12. PubMed ID: 12615251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LC and LC-MS study of stress decomposition behaviour of isoniazid and establishment of validated stability-indicating assay method.
    Bhutani H; Singh S; Vir S; Bhutani KK; Kumar R; Chakraborti AK; Jindal KC
    J Pharm Biomed Anal; 2007 Mar; 43(4):1213-20. PubMed ID: 17118610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography/tandem mass spectrometry.
    Prahl JB; Lundqvist M; Bahl JM; Johansen IS; Andersen ÅB; Frimodt-Møller N; Cohen AS
    APMIS; 2016 Nov; 124(11):1004-1015. PubMed ID: 27546025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry.
    Song SH; Jun SH; Park KU; Yoon Y; Lee JH; Kim JQ; Song J
    Rapid Commun Mass Spectrom; 2007; 21(7):1331-8. PubMed ID: 17340570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDC + Z for tuberculosis treatment in Brazil: a cohort study.
    Braga JU; Trajman A
    BMC Infect Dis; 2015 Feb; 15():81. PubMed ID: 25879615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overestimation of rifampicin during colorimetric analysis of anti-tuberculosis products containing isoniazid due to formation of isonicotinyl hydrazone.
    Mariappan TT; Jindal KC; Singh S
    J Pharm Biomed Anal; 2004 Nov; 36(4):905-8. PubMed ID: 15533688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.